jumped 5.7% to $3.70 after investment research firm Susquehanna Financial Group initiated coverage of the stock with a positive rating.
to a hold rating from a buy, sending shares 1.3% lower to $61.35. Citigroup also downgraded generic drugmaker
from a buy rating to a hold, with a price target of $34. Shares fell 1.4% to $31.24.
named a chief operating officer and a leadership team for its pharmaceutical products division. Frank Harmon, former head of global operations will become COO and Thomas H. Silberg will assume the role of president of the pharmaceuticals business. Shares rose 0.5% to $25.10.
Other movers included
, whose shares lost 8.5% to $5.08,
, up 0.5% to $4.44 and
, down 1.6% to $13.06.
rose 1.6% to $16.52,
was up 6.5% to $10.05,
added 2.5% to $2.43,
Human Genome Sciences
gained 2.9% to $11.40, and
was up 4.3% to $47.97.